Kurt Von Emster
CIK 1252524 · last filed 2026-10-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRSP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 350
SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IAM | Director | — | — | — | $0 | 1 | 2026-10-16 |
| JSPR | Director | — | $0.49 | — | $0 | 1 | 2026-08-04 |
| Jasper Therapeutics, Inc. (JSPRW) Delisted | Director | 21,175 | $0.00 | $4 | -$13.5K | 6 | 2025-07-03 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Director | 18,406 | $32.48 | $597.8K | -$19.00M | 30 | 2024-03-22 |
| PCVX | Director | 4,168,718 | $60.76 | $253.27M | $200.0K | 4 | 2021-06-03 |
| VERA | Director | 2,978,059 | $29.85 | $88.90M | $8.71M | 2 | 2021-05-18 |
| CRSP | Director | 1,261,268 | $50.40 | $63.57M | -$39.41M | 6 | 2019-01-18 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | 1,887,202 | — | — | -$12.92M | 24 | 2018-01-11 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 30,893 | — | — | -$1.74M | 23 | 2013-01-03 |
| FACT | Director | 1,667 | $10.76 | $17.9K | $0 | 3 | 2010-04-21 |
Recent Filings · Page 5 of 11
104 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-02-05 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Sell (S) | −90,098 | -$1.09M | EDGAR |
| 2018-02-01 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Sell (S) | −97,639 | -$1.19M | EDGAR |
| 2018-01-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Mixed | −39,438 | -$480.4K | EDGAR |
| 2018-01-24 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Sell (S) | −138,253 | -$1.44M | EDGAR |
| 2018-01-22 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Sell (S) | −144,216 | -$1.48M | EDGAR |
| 2018-01-11 | CRISPR Therapeutics AG (PZRX) Delisted | Buy (P) | +65,934 | $1.50M | EDGAR |
| 2018-01-09 | CRISPR Therapeutics AG (PZRX) Delisted | Sell (S) | −92,337 | -$2.49M | EDGAR |
| 2018-01-09 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Sell (S) | −4,300 | -$43.9K | EDGAR |
| 2018-01-04 | CRISPR Therapeutics AG (PZRX) Delisted | Sell (S) | −37,754 | -$1.01M | EDGAR |
| 2017-12-27 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Sell (S) | −173,192 | -$1.63M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.